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Introduction
Melanoma skin cancer is an aggressive tumour whose incidence has been steadily increasing 
over the last 50 years, now representing 3% of total tumours. In 2012, more than 232,000 new cases 
of melanoma were diagnosed worldwide; in the same year, mortality estimation calculated 55,500 
deaths from melanoma in the world [1], with an increasing stage-specific mortality rate [2]. The 
treatment of localized disease (stage I and II) is surgical excision, while, in the advanced disease, 
pharmacotherapy is included in the treatment [3]. Chemotherapy was the first therapeutical 
option: Dacarbazine (DTIC), an alkylating agent, was approved in 1974 by US Food and Drug 
Administration (FDA) for the treatment of metastatic melanoma. Later, other chemotherapeutic 
drugs were used, alone or in combination, in several clinical trials, such as Temozolomide (TMZ), a 
combination of Cisplatin, Vinblastine and Dacarbazine (CVD), or Carboplatin and Paclitaxel (CP). 
However, these regimes have been compared with DTIC alone and no significant improvements in 
overall survival were observed, or they elicited important toxic effects, such as myelosuppression, 
peripheral neuropathy and fatigue [4].
A recent report has calculated that less than 5% of patients achieve a complete response with 
DTIC, and the 5-year survival rate is only 2-6% [5]. Recent improvements in treatment effectiveness 
have been obtained with Immunotherapy and Targeted therapy (Table 1).
The immune system plays a very important role in melanoma progression. Indeed, melanoma 
can evade immune response which can be associated with immunosuppression [6]; thus, the 
possibility of re-activating a specific antitumour immune response has been widely explored. IL-2 
and interferon were at first used as adjuvant therapy, but, more recently, very specific modulators of 
the immune response, such as the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed 
Death-1 (PD-1) inhibitors have been approved. CTLA-4 is a protein receptor present on the surface 
of cytotoxic T-lymphocytes, and acts as an inhibitory checkpoint that blocks T-cell activation; 
ipilimumab, the anti-CLTA-4 monoclonal antibody, is able to restore T cell activity [7]. Similar 
to CTLA-4, the PD-1 receptor is expressed on T-cells, and it normally binds to the PD-1 and 2 
Ligands (PD-L1, PD-L2); moreover, it is present on antigen-presenting cells and suppresses T-cell 
activation; pembrolizumab and nivolumab are two anti-PD-1 antibodies that block the interaction 
between PD-1 and its ligands, PD-L1 and PD-L2, thus reactivating the T-cell response [8]. Very 
recently, the first live oncolytic virus therapy against melanoma has been approved by the FDA. 
Imlygic is a genetically modified oncolytic herpes virus, able to replicate within cancer cells, destroy 
them, and produce the immunostimulatory protein GM-CSF (Granulocyte-Macrophage Colony 
Stimulating Factor) [9].
In the last few years, the treatment options for the advanced disease have expanded dramatically, 
thanks to the identification of activating mutations in the genes involved in melanoma progression. 
New molecular targeted therapies have been set up, with the development of small molecular 
inhibitors that target these mutated proteins. In 2011, the FDA approved the first targeted drug 
for the advance melanoma disease, the B-RAF inhibitor Vemurafenib [10]. B-RAF is a Serine/
Threonine Kinase, belonging to Mitogen-Activated Protein Kinases (MAPKs), one of the main 
signal transduction pathways involved in cell proliferation. Vemurafenib, with the more recently 
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Abstract
Melanoma skin cancer is an aggressive tumour with an increasing incidence. In recent years, the treatment 
options for the advanced disease have expanded dramatically with the employment of targeted therapy and the 
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unmet clinical problems. Scientists are expecting a further advance with the application of nanotechnology in 
melanoma treatment and diagnosis. In this review, we present an up-date on the latest pre-clinical studies (2015-
2016) on nanomedicine with potential use in the clinical management of this disease.
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FDA-approved dabrafenib, targets the V600E/K mutated form of 
BRAF, which is carried in 50-60% of cutaneous melanomas [11]. The 
treatment with the BRAFV600E/K inhibitors has been successfully 
used, prolonging both progression-free and overall survival, when 
compared with DTIC [12-14]. Another member of the MAPK 
pathway is the Mitogen-activated protein kinase (MEK), which is the 
primary downstream target of B-RAF. MEK is mutated in about 8% of 
melanomas [15]. MEK inhibitors, such as cobimetinib and trametinib 
are now available on the market for the treatment of advanced 
melanoma (Table 1). Moreover, several clinical trials are on-going for 
testing inhibitory molecules against other activating mutations which 
have been identified in melanoma, such as C-KIT or mTOR (i.e.: Trial 
ID NCT02501551, NCT01280565 and NCT01960829).
Both targeted therapies and immunotherapies are promising 
for advanced melanoma. However, toxicity and/or drug resistance 
remain unmet clinical problems. For instance, after vemurafenib 
treatment, most patients develop resistance after 6 to 7 months [12-
14]; the concurrent administration of ipilimumab and nivolumab, 
although producing a 2-year survival of 79% caused severe immune 
toxicities in 53% of patients treated with this combination, leading 
30% of patients to discontinue this therapy [16,17]. These important 
limitations strongly suggest investigating novel methods of drug 
delivery. With the recent and rapid developments in nanotechnology, 
the incorporation of therapeutic agents into Nanoparticles (NPs) can 
be the possible answer. The use of drug-loaded NPs can improve the 
solubility of poorly water-soluble drugs, optimize pharmacokinetics, 
increase drug half-life, improve bioavailability, achieve targeting 
specificity, diminish drug metabolism, with the ultimate goals of 
improving efficacy, overcoming drug resistance, and reducing 
toxicity.
Several types of NPs for cancer treatment are currently under 
investigation, including liposomes, Solid Lipid Nanoparticles 
(SLNs), polymeric micelles, nanospheres, dendrimers, nanotubes, 
mesoporous silica NPs, quantum dots, super paramagnetic iron 
oxide NPs, and gold NPs [18-21]. Several nanomedicines for cancer 
treatment have been FDA-approved, such as pegylated doxorubicin 
(Doxil) in ovarian and breast cancer, albumin-bound paclitaxel 
nanospheres (Abraxane) and liposome-encapsulated doxorubicin 
(Myocet) in breast cancer [22]. For melanoma, nanomedicines are 
not yet FDA-approved, but there are several on-going trials (Table 2). 
Beside the therapeutical option, another interesting application 
for the nanotechnological platforms consists of their use for diagnostic 
purposes. Several types of NPs, containing non-radioactive tracers, 
can be useful for visualizing the disease site, such as the presence 
of metastatic melanoma cells into the lymph nodes. Moreover, the 
possibility of combining the therapeutic and the diagnostic abilities, 
referred to as theranostic, is receiving growing interest [23-24]. Table 
3 also reports the on-going trials having a diagnostic or theranostic 
purpose.
The opportunities offered by nanomedicine for melanoma 
treatment, diagnosis, and theranostic applications have been 
extensively reviewed [18-24-27]. In this review we present an up-
date on the latest pre-clinical studies (2015-2016) of the use of 
nanotechnology in melanoma treatment and diagnosis.
Table 1: FDA-approved drugs in Immunotherapy and Targeted therapy.
Targeted therapy
Drug Activity FDA-Approved
Cotellic (Cobimetinib, Genentech) MEK inhibitor Nov 2015
Trametinib (Mekinist, GlaxoSmithKline) MEK Inhibitor May 2013
Dabrafenib (Tafinlar, GlaxoSmithKline) Inhibitor of V600E-mutated form of BRAF May 2013
Vemurafenib (Zelboraf, Roche) Inhibitor of V600E-mutated form of BRAF Aug 2011
Immunotherapy
Drug Activity FDA-Approved
Talimogene laherparepvec "T-Vec" (Imlygic, 
Amgen)
Oncolytic effects and immunomodulating effect by producing GM-CSF (granulocyte-
macrophage colony-stimulating factor) Oct 2015
Pembrolizumab (Keytruda, Merck) PD-1 inhibitor Set 2014
Nivolumab (Opdivo, Bristol-Myers Squibb) PD-1 inhibitor Dec 2014
Peginterferon alfa-2b (Sylatron, Merck) Peginterferon alfa-2b with immunomodulating action Apr2011
Ipilimumab (Yervoy, Bristol-Myers Squibb) CTLA-4 inhibitor Mar 2011
IL-2 (Proleukin-Chiron) IL-2 with immunomodulating action Jan 1998
Interferon alfa-2b recombinant (Intron A, 
Schering-Plough) Interferon alfa-2b with immunomodulating action Dec 1995
Figure 1: Number of Publications per year on Nanomedicine and Melanoma. 
Number of publications per year obtained on PubMed with the following 
query: “(Nanoparticle or Nanomedicine) and melanoma”. A great increase is 
evident from the year 2008.
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The Use of Nanotechnology in Melanoma Treatment
The interest in nanotechnology for the treatment and diagnosis 
of melanoma has grown exponentially over the past five years (Figure 
1). We found 79 publications in the period 2015-March 2016, about 
latest pre-clinical studies on nanotechnology applied to melanoma 
research. Most of the publications (65, representing the 82%) are 
about the identification of new type of anti-melanoma treatments. A 
small percentage (7 publications representing the 9%) is focused on 
diagnosis. Seven publications (9%) are devoted to the development of 
nanocarriers able to combine both therapy and diagnosis (theranostic) 
(Figure 2).
By considering the publications related to new nanotherapeutic 
approaches, we can further subdivide them according to the type of 
treatment: immunotherapy, the treatments that can restore or enhance 
the immune system’s ability to fight cancer; cytotoxic chemotherapy, 
which employs the common cytotoxic drugs; new anticancer agents, 
which explore the anti-tumoral properties of new molecules of 
different origins; targeted therapy, using drugs that interfere with 
specific molecules involved in tumor growth and survival; physically-
driven therapy, which involves the use of photosensitizing agents; 
combined therapy, which combines the contemporary use of two 
or more therapeutical strategies; cellular targeting, which explores 
several strategies to enhance the active tumor targeting, such as the 
functionalization of nanocarriers or the stimuli-responsive nano-
formulations; and theranostic, nanocarriers  able to combine both 
therapy and diagnosis. In the 2015-2016 period, the nanoformulations 
were most commonly employed for immunotherapy (21%), followed 
by cellular targeting (18%), physically-driven therapy (15%), and new 
anti-cancer (14%) studies (Figure 3). A graphical overview of these 
nanotherapeutic approaches for melanoma in 2015-16 is showed in 
Figure 4.
Cancer Immunotherapy 
In recent years, we have witnessed tremendous progress in the 
development of the cancer immunotherapy, especially for melanoma 
tumours. Several immunomodulators are already in clinic (Table 1) 
and the scientists are expecting further advances with nanomedicine 
applications. 
Table 2: Ongoing clinical trials involving NPs and melanoma (from www.clinicaltrials.gov and from www.isrctn.com).
Nanoformulations Disease Phase Results Trial ID
Cancer immunotherapy
Pegylated Interferon-alpha-2a Patients With Malignant Melanoma IIA-IIIB III ongoing, not recruiting NCT00204529
Pegylated Interferon-alpha-2b Melanoma stage I-III 0 recruiting NCT00871533
Cytotoxic chemotherapy
Albumin-bound paclitaxel (Nab-paclitaxel) Pediatric Patients With Recurrent/ Refractory Solid Tumours, including melanoma I - II recruiting NCT01962103
Targeted therapy
Liposomes containing shRNA against human 
stathmin 1 Several metastatic tumours, including melanoma I
ongoing, not 
recruiting NCT01505153
Combined therapy
Nab-paclitaxel and bevacizumab vs. ipilimumab Patients With Stage IV Melanoma That Cannot Be Removed By Surgery II
ongoing, not 
recruiting
NCT02158520
Nab-paclitaxel in combination with bevacizumab Patients With Stage IV Melanoma That Cannot Be Removed By Surgery II
ongoing, not 
recruiting NCT01879306
Nab-paclitaxel in combination with bevacizumab Patients With Stage IV Melanoma That Cannot Be Removed by Surgery I recruiting NCT02020707
Rituxan and Nab-paclitaxel Patients With Inoperable Stage III and IV Malignant Melanoma II recruiting NCT02142335
nab-paclitaxel in combination with PLX7486 
(tyrosine kinase inhibitor) and gemcitabine
Patients With Advanced Solid Tumours, including 
melanoma I recruiting NCT01804530
Liposomal Cytarabine (DepoCytTM) in combination 
with lomustine and brain radiotherapy Leptomeningeal Metastasis From Malignant Melanoma I recruiting NCT01563614
Diagnosis and imaging
Magnetic Nanoparticles Using magnetic tracers to find the sentinel lymph nodes in patients with Melanoma skin cancer III recruiting ISRCTN15768185
Silica-based nanoparticles labeled with the 
fluorophore cyanine 5.5, and functionalized with 
RGD
For Image-Guided Intraoperative Sentinel Lymph Node 
Mapping in Head and Neck Melanoma, and others 
cancers
0 recruiting NCT02106598
Figure 2: Nanomedicine and Melanoma in the 2015-2016 time period. Type 
of publications in the 2015-2016 time period, expressed as percentage. Most 
of the publications (82%) are about the identification of new types of anti-
melanoma treatments. A small percentage (9%) is focused on diagnosis. 
9% of the publications are devoted to the development of nanocarriers able 
to combine both therapy and diagnosis (theranostic).
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Inhibition of the immunosuppressive cells: One of the possible 
strategies of cancer immunotherapy is to eradicate the immune 
suppressor cells, such as the regulatory T-lymphocytes (Treg) and 
the Myeloid-Derived Suppressor Cells (MDSCs), a heterogeneous 
population of immature myeloid cells that suppress effector T cell 
responses. Similar to anti-CTLA-4 drugs, Li and collaborators [28] 
developed NPs containing a siRNA targeting CLA-4 (NPsiCTLA-4). 
They demonstrated, in the mouse model bearing B16 melanoma, that 
NPsiCTLA-4 was able to activate the anti-tumour immune responses, 
as demonstrated by the increase of anti-tumour CD8+T cells, and the 
decrease of inhibitory T regulatory cells among tumour infiltrating 
lymphocytes [28]. An interesting strategy for the ablation of MDSCs 
was proposed by Jeanbart and collaborators [29], which have 
developed polymer micelles loaded with 6-Thioguanine (MC-TG), a 
cytotoxic drug used in the treatment of myelogenous leukemia, with 
the aim of killing MDSCs. After the injection of micelles in B16-F10 
melanoma-bearing mice, they found a depletion of MDSC, as well as 
a higher efficacy of adoptive T cell therapy. 
Toll-like receptors (TLR) agonists: Recently, tumour-specific 
immune activation was achieved with the agonist of Toll-Like 
Receptors (TLRs). Their engagement leads to innate and adaptive 
immune responses, which can have anti-tumoural effects [30]. For 
instance, it has been demonstrated that TLR agonists may indirectly 
kill chronic lymphocytic leukemia cells, by enhancing the activity of 
natural killer and tumor-reactive T cells [31]. Moreover, clinical trials 
demonstrated the successful treatment of cutaneous tumors, such 
as the basal cell carcinoma with imiquimod, an immunoresponse 
modifier affecting TRL-7, which is able to stimulate both the innate 
immune response and the cell-mediated immune system, via 
induction of cytokines [32].
With this aim, Zhu and collaborators [33] developed a new 
nanocarrier containing analogs of the unmethylated Cytosine-
phosphate-Guanine (CpG), a class of potent adjuvants that activate 
TLR9, located in the endolysosome of many Antigen-Presenting 
Cells (APCs). This nanoformulation, obtained by self-assembling 
concatemer CpG analogs and Magnesium Pyrophosphate (Mg2PPi), 
had a rapidly uptake by APCs. In the endolysosomes compartment, 
Mg2PPi was dissolved, due to the acidic environment, and CpG 
analogs were able to activate TRL9. Thus, APCs started to secrete 
proinflammatory and co-stimulatory factors, leading to the tumour 
growth inhibition in B16-F10 melanoma-bearing mice [33].
Cancer vaccines: The use of nanoparticle-based vaccines is a recent 
application of the field of nanomedicine [30]. A specific antigens, 
such as ovalbumin (OVA), or tumour-specific antigens with or 
without adjuvants, loaded in nanostructure, can be delivered to 
the “in situ” DCs for efficient antigen presentation and consequent 
stimulation of the antigen-specific response against cancer cells. 
Hong and collaborators [34] developed new antigen-encapsulating 
NPs, loaded with OVA, and coated with interLeukin-15 (IL-15) and 
its receptor IL-15Rα (IL-15: IL-15Rα), which functions as a vaccine 
adjuvant. After the treatment of DCs, they found an enhanced ability 
to stimulate antigen-specific CD8+T cell responses. Moreover, the 
treatment with (IL-15: IL-15Rα)-coated NPs, in an animal model 
of murine melanoma, significantly increased the survival rate, in 
comparison with monovalent (IL-15: IL-15Rα) treatment. Similar 
to IL-15, α-GalactosylCeramide (α-GalCer) has been regarded 
as a potent vaccine adjuvant. Dolen and collaborators [35] have 
encapsulated both in a single NP and they found that, in mice, a 
single immunization with OVA+α-GalCer NPs provided substantial 
protection from melanoma tumour formation and even delayed the 
growth of already established tumours. 
Poly Lactic-co-Glycolic Acid NPs (PLGA-NP) have been 
extensively studied for vaccine delivery and have been reported to 
target dendritic cells naturally through phagocytosis with efficient 
delivery of the vaccine components. OVA containing PLGA-NPs were 
loaded in thermoresponsive hydrogels, made of PolyEthyleneGlycol-
P o l y C a p r o L a c t o n e - P o l y L a c t i d e - P o l y C a p r o L a c t o n e -
PolyEthyleneGlycol (PEG-PCL-PLA-PCL-PEG) [36]. The hydrogels 
stimulated both cellular and humoral responses, and stimulated 
effective anti-tumour responses in an animal melanoma tumour 
model. Tumour-Associated DCs (TADCs), compared to normal 
DCs, are less responsive to TLR stimulation, which has been related 
to STAT3 hyperactivity. Luo and collaborators [37] developed new 
nanovaccines with the aim to overcome DC dysfunction. They have 
co-encapsulated the Poly I:C (PIC), a TLR3 agonist, the OVA antigen, 
Figure 3: Different Nanotherapeutic approaches for Melanoma Treatment 
in the 2015-2016 time period. Number of publications in the period 2015-
2016, expressed as percentage, relative to the different nanotherapeutic 
approaches for melanoma treatment.
 
Figure 4: Overview of the current preclinical nanotherapeutic approaches 
for melanoma treatment in the 2015-2016 time period.
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and the siRNA targeting STAT3, in PEG-b-Poly(L-Lysine)-b-Poly(L-
Leucine) (PEG-PLL-PLLeu) polypeptide micelles. These micelles 
showed a strong tumour regression effect with prolonged survival, 
accompanied by anti-tumour immune responses in B16 melanoma-
bearing mice. Silva and co-authors [38] co-delivered OVA and two 
TRL ligands, such as Poly(I:C) and CpG in mannose-functionalized 
NPs. The presence of this sugar, on the surface of the NPs, enhanced 
the up-take from the antigen-presenting cells, which have the 
mannose receptors. This nanovaccine decreased the growth rate of 
murine B16F10 melanoma tumours. A gene-carrier system based 
on chitosan NPs with immunomodulant activity was developed by 
Yan and collaborators [39]. These NPs were loaded with a plasmid 
containing the fusion of two genes: the extracellular domain of the 
activating receptor NKG2D (Natural-Killer Group 2, member D) and 
the IL-15 gene. The protein showed the ability to activate NK and 
CD8+T cells, thus enhancing the antitumour activity of the immune 
system. Indeed, intramuscular injection of fused gene NPs suppressed 
tumour growth and prolonged survival of melanoma-bearing mice.
The use of specific antigens for melanoma can improve the efficacy 
of nanovaccines. Several authors, in 2015-2016, developed new 
nanovector containing specific melanoma antigens and adjuvants. 
PLGA-based NPs (PLGA-NPs), carrying the melanoma antigen 
(hgp10025-33) and, as adjuvant, the TRL4 agonist MonoPhosphoryl 
Lipid (MPLA), were recently reported [40]. Interestingly, the PLGA-
NPs were coated with erythrocyte membranes, by virtue of their 
easy isolation and intrinsic biocompatibility [41]. PLGA-NPs were 
further modified by adding the mannose on the surface, to actively 
target APCs in the lymphatic organ. This nanovaccine demonstrated 
superiority to an ordinarily used vaccine formulation against 
tumour prevention, growth, and metastasis in B16-F10 bearing mice 
[40]. Zhuang and collaborators [42] proposed a Lipid-coated Zinc 
Phosphate hybrid NP (LZnP NP), able to co-deliver both the tumour 
specific antigens, represented by a multi-peptide (TRP2180-188 
and HGP10025-33) and a TRL4 agonist (MPLA) as adjuvant. This 
nanoformulation, with the size of 30 nm, was intradermically injected 
in C57BL/6 mice. Ten days after the last immunization, C57BL/6 
mice were inoculated subcutaneously B16-F10 melanoma cells. Mice 
exhibited antitumour immunity, as demonstrated by the secretion of 
cytokines and the increased CD8+T cell response. This antitumour 
effect elicited an inhibition of melanoma growth, more consistent 
when compared with the treatment of free antigens [42]. The gp100 
melanocyte differentiation protein epitope was loaded into NPs, 
obtained by engineering the E2 subunit of pyruvate dehydrogenase 
[43]. Moreover, this non-viral cage contained CpG DNA molecules, 
able to increase the antigen-specific anti-tumour responses following 
immunization, since CpG sequences are similar to those found 
in bacterial DNA. They succeed in obtaining higher CD8+T cell 
activation, as well as an increased survival of animals bearing B16 
melanoma by 40%, compared to PBS-treated animals [43].
The melanoma immunotherapy can also take advantage of the 
treatment with plant-derived Viral NPs (VNPs), since they are natural 
nanomaterials, biodegradable and biocompatible. They can be used as 
a carrier for drug delivery or for imaging applications, or they can 
use as an adjuvant immunostimulatory molecules, able to activate the 
anti-tumoural T-cell response [44]. For instance, it has been shown 
that the self-assembling virus-like NPs from Cow Pea Mosaic Virus 
(CPMV) [45] and the Papaya Mosaic Virus nanoparticle (PapMV) 
[46] suppress melanoma metastatic cancer in animals.
Cytotoxic Chemotherapy
In melanoma, the response rates to the common cytotoxic 
drugs are very low. Thus, the scientists do hope to develop effective 
anticancer treatments thanks to nanotechnology, which will increase 
the effectiveness of anti-cancer treatments. Gold NPs (AuNPs) 
conjugated with doxorubicin (Au-Dox) are receiving great attention. 
Zhang and collaborators [47] demonstrated that the intratumoural 
injection of ultra-small Au-Dox is effective against melanoma in 
immunocompetent mice bearing murine B16 melanoma cells and 
in nude mice bearing human SK-MEL-28 xenograft. Moreover, 
Tawagi and collaborators [48] compared the toxicity of Au-Dox 
in B16 melanoma cell lines and cardiomyocytes, measured by real-
time growth assays and Fluorescence Lifetime Imaging Microscopy 
(FLIM). They demonstrated that cardiomyocytes were more sensitive 
than B16 cells to Dox alone, but were dramatically less sensitive to 
Au-Dox. On the contrary, Au-Dox was more effective in inducing cell 
death of B16 melanoma cells, compared to Dox alone. The different 
patterns of Au-Dox in the two cell types can explain the differential 
toxicity: while Au-Dox concentrated in the nuclei of B16 cells, it 
remained endosomal in cardiomyocytes. Kaiser and collaborators 
[49] demonstrated an enhanced antitumoural activity of docetaxel, 
when loaded in Acid-Prepared Mesoporous Spheres (APMS-TEG). 
This nano-formulation was effective in MelJuSo, UACC903, and 
WM1205 melanoma cell lines at a nanomolar concentration, thus 
suggesting a potential use in clinic. A Graphene Oxide (GO) sheet 
conjugated with paclitaxel (PTX) was successfully employed in B16 
melanoma-bearing C57 mice [50].
An interesting study has determined the influence of nanoparticle 
size on targeting lymph node metastases [51]. The authors delivered 
micelles, loaded with the platinum anticancer drug, with different 
diameters, in a syngenic melanoma model. The targeting of lymph 
node metastases was compared with results obtained with the 
clinically used Doxil having a diameter of 80 nm. They found that 
the sub-50 nm micelles were more efficient in reaching lymph node 
metastasis, having a higher capability in extravasating from the blood 
and penetrating into the metastatic tumour.
New Anticancer Agents
The anti-melanoma properties of several plant extracts, or 
derivatives, have been explored in the last two years.
Dwivedi and collaborators [52] have studied the antitumoural 
effect of artemisone, an artemisinin derivative, isolated from the 
plant Artemisia annua and currently used as an antimalarial drug, on 
melanoma cells in vitro. They loaded Artemisone in nano-vesicular 
niosomes and in solid lipid NPs, demonstrating in both cases enhanced 
antiproliferative effects against human melanoma A375 cells, with 
respect to the free drug. Moreover, these nanoformulations had 
negligible toxicity towards normal skin cells. Later, they performed 
in vitro skin permeation studies with both nanoformulations. They 
found out that, in the stratum corneum-epidermis, artemisone-
SLNs were found at higher concentration compared to than the 
artemisone-niosomes, and that, in the epidermis-dermis, artemisone 
was only detected after application of the SLN formulation. These 
results suggest the possible topical delivery of artemisone-SLNs in 
treatment of melanoma [53].
Hu and collaborators [54] have developed new NPs loaded 
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with saikosaponin, a biologically active compound extract from the 
Bupleurum chinense, with anti-melanoma activity “in vitro” and 
“in vivo”. They were able to demonstrate that saikosaponin-d NPs 
enhanced the antiproliferative activity against melanoma cells, and 
induced apoptosis through the mitochondrial pathway.
The plant-derived curcumin, loaded into chitosan-coated NPs 
was orally administered to the B16F10 metastatic melanoma bearing 
mice, obtaining an enhanced anti-tumoural activity [55].
Gismondi and collaborators [56] developed novel Detonation 
NanoDiamonds (DNDs), which are new nanoparticles produced by 
detonation of explosive Carbon materials. They loaded the Citropten 
(5,7-dimethoxycoumarin) agent, a plant secondary metabolite into 
DNDs, and demonstrated that this nanovehicle was able to reduce 
B16-F10 tumour cell growth.
The herb-derived compound triptolide (TP), with anti-angiogenic 
properties, was loaded into methoxy poly(ethylene glycol)-block-
poly(ε-caprolactone) micelles by Wang and collaborators [57]. 
In B16-F10 melanoma-bearing mice they demonstrated that the 
nanovehicle enhanced the TP accumulation in tumour tissues, 
increased the survival time and inhibited angiogenesis.
4-Hydroxynonenal, an endogenous compound derived from 
lipid peroxidation was studied as an anti-melanoma agent [58]. A 
new type of lipid nanocapsule, based on β-Cyclodextrin-poly(4-
acryloylmorpholine) conjugates, was designed to enhance its solubility 
and stability. HNE loaded in the nanocapsules was more effective than 
free HNE in inhibiting proliferation of several tumour cancer cells, 
including melanoma. Moreover, the effect of these new nanocapsules 
on a three-dimensional human reconstructed model of skin 
melanoma was evaluated. Two diverse treatments were performed: 
one in the medium, mimicking the parenteral administration, and the 
other onto the epidermal surface, mimicking the topical treatment. 
Both treatments were more effective than free HNE on melanoma 
cell growth inhibition. Interestingly, the encouraging results obtained 
with the topical administration on the epidermal surface could open 
new perspectives in melanoma treatments [58].
Other chemical compounds loaded into NPs were successfully 
employed for melanoma treatment, such as the novel synthetic tubulin 
inhibitor, 2-(1H-indol-5-yl)thiazol-4-yl)3,4,5-trimethoxyphenyl 
methanone (abbreviated as LY293) [59], and the Cerium oxide CeO2 
[60].
Targeted Therapy
Most recent preclinical studies in the field of targeted therapy 
explored the use of nucleic acid for melanoma treatment.
Li and collaborators [61] developed new NPs able to carry 
the DNA for the pro-apoptotic gene PUMA (p53 up-regulated 
modulator of apoptosis). In particular they used the cationic Polymer 
Polyethylenimine (PEI), widely employed for non-viral transfection, 
crosslinked with Sulfosuccinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (Sulfo-SMCC) conjugating Trans-
Activating Transcriptional activator (TAT). This nanovector 
enhanced the transfection efficiency of PUMA gene in malignant 
melanoma A375 cell, resulting in increased apoptosis.
Polycation based NPs (jetPEI) were used as carrier for the delivery 
of a plasmid expressing the short hairpin RNA (shRNA) against 
the CXC motif Chemokine Receptor 4 (CXCR4) [62], as an anti-
metastatic target. They succeed in obtaining a significant reduction in 
the number of pulmonary metastatic nodules (50%) in animals that 
received a retro orbital injection of jetPEI CXCR4 1 shRNA.
Hundt and collaborators [63] set up a method to monitor by MR 
imaging the antiangiogenic gene therapy in M21 melanoma-bearing 
mice. As the antiangiogenic gene, they chose the dominant-negative 
mutant form of Raf-1 (Raf-1-). The plasmid containing Raf-1- was 
loaded into RGD-targeted sNPs and was given to the animals. They 
found that the targeted gene delivery therapy induces significant 
changes in Magnetic Resonance Imaging (MRI) and that there was 
an excellent correlation between MRI and histological results, which 
were direct effect of the gene delivery therapy.
Beside the employment of the nucleic acids, specific inhibitors 
were also studied, such as the Sn-2 lipase-labile, an inhibitor of the 
oncogene c-myc [64] and glycomimetic (P-3F(ax)-Neu5Ac), an 
inhibitor of the sialic acid, frequently over expressed on cancer cell 
surfaces and contributing to the metastatic process [65].
A nanovector for the imatinib mesylate, a tyrosine-kinase 
inhibitor already in clinical use for several tumours, was developed 
by Labala and collaborators [66]. This nanoformulation consists of a 
layer-by-layer polyelectrolyte coated AuNP (LbL-AuNP) and it was 
specifically designed for the ionophoretic transport into skin.
Physically-Driven Therapy
Therapies inducing hyperthermia: Photo Thermal Therapy (PTT) 
involves the use of light and a photosensitizer to generate heat for 
therapeutic purposes. Gold-based NPs are widely used for this 
purpose, since after the irradiation, they generate a localized heat 
so as to damage a region of interest [67]. A Gold-Ferrite Nano 
Composite (GFNC) was obtained by Heidari and collaborators [68], 
as a photo thermal agent in melanoma-bearing mice. They have 
demonstrated a higher necrotic surface tumour area in mice receiving 
GFNC injection and laser irradiation. Wang and collaborators [69] 
developed gold nanoshell capsules, which easily penetrate melanoma 
cells. After a mild laser irradiation, they observed a consistent ablation 
of malignant melanomas.
Magnetic Field Hyperthermia (MFH) treatment has received great 
attention from the scientific community, since this therapeutic option 
elicits the heating of magnetic NPs by time-varying magnetic fields. 
Blanco-Andujar and collaborators [70] demonstrated that human 
melanoma cells undergo apoptosis upon exposure to citric acid-
coated iron-oxide NPs, followed by a Magnetic Field Hyperthermia 
(MFH) treatment.
The ability of Radio Frequency (RF) radiation to heat human 
tissues has been known for a long time, and now this knowledge 
can be exploited in cancer therapy. Haghniaz and collaborators [71] 
have explored the potential use of Dextran-coated (Dex) Lanthanum 
Strontium Manganese Oxide (LSMO) NPs, as a hyperthermia agent 
in the treatment of cancer. B16-F1 melanoma cells were exposed to 
Dex-LSMO NPs and heated using a radiofrequency generator, finding 
that the cell death increased in a time-dependent and temperature-
dependent manner.
Photo dynamic therapy (PDT): Photo Dynamic Therapy (PDT) 
uses nontoxic photosensitizing agents and a light source to treat 
cancers. Under light exposure, these chemical compounds are excited 
and are able to produce ROS, able to kill cancer cells. Ogawara and 
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collaborators [72] developed a new nanoformulation for cancer PDT. 
They encapsulated Photoprotoporphyrin IX DiMethyl Ester (PppIX-
DME), a hydrophobic porphyrin derivative, into polymeric NPs 
composed of polyethylene glycol and polylactic acid block copolymer 
(PN-Por). An “in vitro” phototoxicity study clearly indicated the 
significant phototoxicity of PN-Por for three types of tumour cells, 
(including B16-BL6 melanoma cancer cells), in a PppIX-DME 
concentration-dependent fashion [72]. Thus, the use of Zinc Oxide 
(ZnO) NPs in anticancer treatment has become a promising strategy, 
due to their excellent photo-oxidation activity.
Under light activation, ZnO, or a derivative, is able to induce ROS 
production, thus killing cells via oxidative stress. However, ZnO has 
a low photocatalytic decomposition rate and Arooj and collaborators 
[73] demonstrated that metal ions such as Silver (Ag) improve their 
activity. Under daylight exposure, ZnO: Ag nanocomposites induced 
cell death of human malignant melanoma (HT144) more efficiently 
that ZnO alone. Interestingly, these ZnO: Ag nanocomposites killed 
melanoma HT144 cells more efficiently than normal Human Corneal 
Epithelial Cells (HCEC). Wang and collaborators [74] succeeded 
in treating cultured melanoma cells and a B16 murine melanoma 
model with Near-InfraRed (NIR) Plasmonic copper sulfide (Cu2-xS) 
Nano Crystals (NCs), followed by NIR irradiation. Interestingly, they 
concluded that the therapeutic effect was due to a combination of the 
photo thermal heat mechanism (Photo Thermal Therapy, PTT) and 
the photodynamic activity, via the production of high levels of ROS.
Araki and collaborators [75] explored the possibility that the 
Photo Dynamic Therapy (PDT) towards the tumour vasculature 
(Photo-triggered tumour Vascular Treatment, PVT) may enhance 
the vascular permeability, leading to augmented Enhanced 
Permeability and Retention (EPR). B16 tumour-bearing mice, with 
low permeable vasculature, were treated with liposomal paclitaxel 
(PL-PTX) and a hydrophobic porphyrin derivative in polyethylene 
glycol-block-polylactic acid NPs was used as a photosensitizer. The 
authors demonstrated that the PVT treatment enhanced the anti-
tumour activity elicited by PL-PTX, thus augmenting the EPR effect 
in a model of low permeable tumour vasculature.
Non-thermal atmospheric-pressure plasma: Non-thermal 
atmospheric-pressure plasma, also named cold plasma, is defined as 
a partly ionized gas and it is a new innovative approach to medicine 
[76]. Recently, its anti-tumoural activity has emerged and gained 
attention. However, its action is not specific. Choi and collaborators 
[77] succeeded in enhancing the capability of the cold plasma in 
specifically killing melanoma cells. They have targeted NEU (human 
epidermal growth factor receptor 2) protein, which is frequently over-
expressed in the cell membrane of melanoma cells, using anti-NEU 
antibody-labeled gold NPs. The labeled NPs preferentially targeted 
melanoma cells rather than normal keratinocytes. Both cells were 
exposed to the cold plasma and they found the death rate of melanoma 
cells was significantly higher than that of normal keratinocyte cells.
Combined Therapy
Several combination therapies have been FDA-approved for 
melanoma treatment (i.e. nivolumab plus ipilimumab; trametinib 
plus dabrafenib), and studies on other combinatory regimens are 
on-going in many trials. Thus, the researchers continue exploring 
several types of combinations in pre-clinical studies, involving 
nanotechnological carriers.
Combining two chemical agents: Ruttala and collaborators [78] 
have developed a liposome carrier containing two chemotherapeutic 
agents, paclitaxel (PTX) and curcumin (CUR). Via a thin-film 
hydration technique, they encapsulated the PTX-loaded Albumin 
NPs (APN) in PEGylated hybrid liposomes containing CUR (CL-
APN). This co-loaded delivery system has shown a higher cytotoxic 
effect on several tumour cell lines, including B16-F10 melanoma 
cells, compared to single free chemotherapeutic drugs or single drugs 
encapsulated in the respective nanocarrier.
Recently, glutamate receptor antagonists, mainly used in 
the treatment of many neuronal diseases, have been proposed as 
anticancer agents. Tan and collaborators [79] developed Mesoporous 
Silica NPs (MSNPs) loaded with both an ionotropic Glutamate (iGlu) 
receptor antagonist, the 4-Hydroxyphenylacetyl spermine (L1), and 
Dox. Moreover, Dox was trapped within the MSNPs by a redox-
cleavable linker, thus being able to be released upon exposure to 
glutathione. The authors demonstrated an enhanced antitumoural 
effect of L1 and Dox co-delivering on B16-F10 melanoma cells in 
vitro.
Combining chemical agent with targeted therapy: A porous silicon-
based Micro/Nano Composite (MNC) has been designed, able to 
co-deliver a chemotherapeutic drug, such as Docetaxel, and a small 
interfering RNA (siRNA) against BRAF. The MNC was more effective 
in inhibiting tumour growth and reducing lung metastasis in a mouse 
melanoma model [80].
Doddapaneni and collaborators [81] designed a novel PEG-PCL 
polymer able to contain three drugs against melanoma: docetaxel 
(targeting microtubules), everolimus and LY294002 (two inhibitors 
of mammalian target of rapamycin, mTOR). They were able to 
modify the surface charge of the NPs, obtaining neutral, partially 
charged, or fully charged surface, with the aim of having preferential 
uptake and accumulation in the lymphatic system, in mice injected 
subcutaneously. Two metastatic melanoma mouse models with the 
two major mutations (NRASQ61K and RXRα) found in human 
melanoma, were used for the in vivo studies. After NPs injection, they 
found that the partially charged NPs have the highest potential in 
treating metastatic melanoma, demonstrating that the surface charge 
is a critical parameter for the lymphatic uptake [81].
Combining chemical agent with radiotherapy: Li and collaborators 
[82] succeeded in establishing a Pluronic® F127-based thermosensitive 
hydrogel (Au-Dox-Gel) containing gold NPs (AuNPs), used as 
radio sensitizer and Dox, the chemotherapeutic drug, to improve 
cancer chemo radiotherapy. Indeed, after radiation, tumour sizes in 
melanoma B16 bearing mice were significantly decreased by Au-Dox-
Gel compared to control mice.
Combining chemical agent with immunotherapy: Chemotherapy 
with immunotherapy is a regimen generally referred to as 
‘BioChemoTherapy’ (BCT). In this respect, Zhao and collaborators 
[83] have co-delivered two types of NPs in B16-F10 melanoma-
bearing mice, one carrying the vaccine antigen and the second loaded 
with the chemotherapeutic agent. As anti-cancer drug, they have 
used the triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9(11)-
dien-28-oate (CDDO-Me) loaded in PLGA-NPs. The antitumoural 
mechanisms of CDDO-Me include induction of apoptosis and 
modulation of several signal transduction pathways involved in 
tumour cell proliferation, but it can also block furthermore the 
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immune suppressive function of Myeloid-Derived Suppressor Cells 
(MDSCs) and improve the immune response to cancer. The second 
nanovector consisted of the self-antigen tyrosinase-related protein 
2 (Trp2) peptide, a melanocyte differentiation antigen, loaded in a 
Lipid-Calcium-Phosphate NanoParticle (LCP-NP). The authors 
demonstrated that the intravenous delivery of CDDO-Me loaded 
in PLGA-NP, combined with the subcutaneous Trp2 vaccination, 
resulted in an increase of anticancer activity compared to Trp2 
vaccine alone in B16-F10 melanoma-bearing mice [83].
Enhancing the Cellular Targeting
Two main strategies are in use to enhance active tumour targeting. 
The first consists of the decoration of the surface of the nanocarrier 
with ligands (i.e. antibodies, aptamers, peptides, sugars) to allow for 
the homing of the drug to a specific target site. The second approach 
is the stimuli-responsive delivery strategies, in which the drug release 
can be achieved within a tumour in response to a cancer-specific 
stimulus.
Functionalized nanocarriers: A well-known peptide used in targeting 
nanocarriers is the arginine-glycine-aspartic (RGD) peptide, which is 
the minimal binding domain of fibronectin necessary to recognize 
cell surface αvβ3/αvβ5 integrins, frequently over expressed on cancer 
cells and tumour vasculature. Zhao and collaborators [84] enhanced 
the hydrosolubility of the anti-cancer agent curcumin with a PEG-
PLA micelle-based drug delivery system. These PEG-PLA micelles 
were functionalized with the αvβ3 integrin-targeted peptide RGD. 
The authors showed that RGD-functionalized PEG-PLA micelles 
containing curcumin had a stronger inhibition of tumour growth 
in B16 tumour-bearing mice, compared with non-RGD modified 
PEG-PLA micelles. Similar results were obtained by Makino and 
collaborators [85] in B16-F10 melanoma-bearing mice with PEG 
micelles loaded with platinum anticancer drug and decorated with 
the RGD peptide. Moreover, they demonstrated the cyclic RGD 
peptide (cRGDs) have antitumour activities themselves, since it has 
been shown that they can inhibit tumour growth and metastasis 
by interfering with the angiogenesis or the integrin-dependent 
metastatic processes.
Hyaluronan (HA) is another interesting molecule which has 
been explored for active targeting. This non-sulfated polysaccharide 
is being recognized as an important regulator of cancer progression 
and is a ligand for CD44, a transmembrane glycoprotein abundantly 
expressed in many malignant tumours and present on many types of 
Cancer Stem Cells (CSCs) [86]. An enhancement of anti-melanoma 
activity was then observed after HA-decorated nanocarrier treatments 
in melanoma-bearing mice [87,88].
Interesting results on enhanced anti-melanoma activity have 
been obtained with several other molecules used for active targeting, 
such as anisamide, a small molecule of benzamide specific ligand 
for the Sigma-1 receptor, highly expressed by tumour cells [89]; 
the tumour-penetrating peptide RPARPAR [90], able to bind to 
the cell surface Neutrophilin-1 receptor (NRP-1), with essential 
roles in vascular biology and which is over expressed in angiogenic 
endothelial cells and in tumour cells; the tumour homing peptide 
GKRK [90], ligand for the receptor p32, a mitochondrial chaperone 
protein, aberrantly expressed at the surface of activated cells such 
as tumour blood and lymphatic endothelial cells, tumour cells, and 
tumour-associated macrophages; and the Polydopamine (PDA), a 
mimic of the specialized adhesive foot protein Mefp-5 (mytilus edulis 
foot protein-5) secreted by mussels [91].
Stimuli-responsive particles: In the most recent period, scientists 
have focused their attention on pH-responsive nanocarrier and 
enzyme-responsive nanovehicles.
pH-responsive nanovehicles, from acetalated cyclodextrins loaded 
with docetaxel, have demonstrated a dramatically enhanced efficacy 
in a melanoma-bearing nude mouse model [92]. Xu and collaborators 
[93] have developed a pH-sensitive carrier, able to simultaneously 
deliver Dox and Bcl2 siRNA, specifically designed for local treatment 
of lung metastasis. Dox was conjugated onto Polyethylenimine (PEI) 
by using Cis-aconitic Anhydride (CA, a pH-sensitive linker) to obtain 
PEI-CA-Dox conjugates. At acidic pH the drug was released faster. 
Then, the anionic siRNA spontaneously formed a complex with the 
cationic PEI-CA-Dox NPs. This nanoformulation showed higher 
anti-cancer activity in B16F10 melanoma cells in vitro, with respect 
the treatment with either Dox or Bcl2 siRNA alone. Interestingly, 
when it is was directly sprayed into the lungs (with acidic pH), of 
B16-F10 melanoma-bearing mice, the PEI-CA-Dox/Bcl2 siRNA 
complex NPs exhibited enhanced antitumour efficacy compared with 
the single delivery of Dox or Bcl2 siRNA.
Among the enzymes, the Matrix MetalloProteases (MMPs) 
and gelatinases have been selected as the external stimulus for the 
nanocarrier opening, since these enzymes are more highly represented 
in the cancer microenvironment. Jallouk and collaborators [94] 
have designed a new perfluorocarbon NP delivery system activated 
by MMP-9 cleavage, able to carry mellitin derivatives (cytolytic 
peptides derived from bee venom) and obtaining enhanced tumour 
growth suppression in a mouse model of melanoma. Similar results 
were obtained with a novel gelatinase-stimuli nanoparticle, loaded 
with pemetrexed, a new antifolate medicine with antitumoural and 
antimetastatic activity [95].
Finally, a combination of the two types of active targeting 
treatments was presented by You and collaborators [96], which 
designed a complex nanocarrier with three layer: the innermost core 
of PCL loaded with the anti-cancer drug camptothecin (CPT), the 
medium layer containing the folate receptor, for the active targeting 
via functionalization, and the outer part consisting of a PEG layer 
sensitive to MMP2 and MMP9. In presence of the tumour cells, the 
PEG layer would detach from the NPs, due to the higher level of 
MMP2 and MMP9 in the cancer microenvironment, resulting in the 
exposure of folate to enhance the cellular internalization via folate 
receptor-mediated endocytosis, which accelerated the release rate 
of CPT in vivo. These nanovectors showed an enhanced anti-cancer 
activity on melanoma B16 bearing mice.
The Use of Nanotechnology for Imaging and Diagnosis
The presence of Lymph Node (LNs) metastasis is an important 
prognostic factor in melanoma. Nanotechnology can help in 
noninvasive, specific and sensitive detection of LN metastasis. Ultra 
small tumour-targeting inorganic (Silica) nanoparticles have been 
recently proposed as an intraoperative tool for guiding resection of 
sentinel lymph node metastases [97]. The specificity and sensitivity of 
contrast-enhanced MRI lymphography can be improved with the use 
of Gadolinium (Gd)-loaded NPs, as demonstrated by Partridge and 
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collaborators [98] in mice bearing B16-F10 melanoma. Interestingly, 
Zhou and collaborators [99] have demonstrated that Gd-embedded 
Iron oxide nanoplates (GdIOP), functionalized with Zwitterionic 
Dopamine Sulfonate (ZDS) molecules, were uptaken differently by 
B16 melanoma cells and by immune cells, such as macrophages and 
dendritic cells in B16 melanoma-bearing mice. After the addition of 
GdIOP NPs, they demonstrated that they were efficiently uptaken by 
immune cells, whereas melanoma B16 tumour cells showed a lower 
intake. Under T1-T2 dual-modal MRI, this difference generated 
pseudo contrast images, with potential use for the detection of 
tumour metastasis in LNs.
A possible application of nanotechnology is to detect angiogenesis 
in vivo. Melemenidis and collaborators [100] have developed RGD-
targeted NPs of Iron Oxide (NPIO) for MRI of tumour angiogenesis, 
after injection, mice bearing subcutaneous melanoma (B16-F10) 
tumours underwent in vivo MRI. The authors demonstrated the 
specific binding of RGD-targeted NPs loaded with NPIO with the 
αvβ3 expressing neo-vessels of the tumours.
Meir and collaborators [101] have found an interesting method 
to trace immune cells, with the aim to study their fate in cancer 
immunotherapy. T-cells were transduced to express a melanoma-
specific T-cell receptor and then labeled with gold NPs (GNPs) as an 
X-ray Computed Tomography (CT) contrast agent. After injection, in 
mice bearing human melanoma xenografts, whole-body CT imaging 
allowed examination of the distribution, migration, and kinetics of 
T-cells.
Another interesting application of nanotechnology is the 
possibility of detecting and quantifying Circulating Tumour Cells 
(CTCs), since their presence at an early stage of cancer progression 
is of significant prognostic value, even in melanoma cancer [102]. 
However, most of the common methods to detect melanoma 
markers often lack sensitivity or selectivity and often produce false-
positive results. Seenivasan and collaborators [103] proposed an 
electrochemical immunosensing method to detect melanoma cells, 
based on the affinity between cell surface MelanoCortin 1 Receptor 
(MC1R) antigen and anti-MC1R Antibody (MC1R-Ab). The MC1R-
Abs were immobilized in amino-functionalized silica NPs and they 
achieved the very low detection limit of 20 cells/ml for melanoma 
cells.
Theranostic Applications on Melanoma
The possibility to load more than one molecule into a single 
nanocarrier opens the way to theranostic applications, since it allows 
the co-delivery of an anti-tumour agent and a tracer for imaging, 
useful for diagnosis. Bazylinska and collaborators [104] succeeded in 
developing a new nanoemulsion able to carry both DNA, useful for the 
gene transfer strategy in cancer treatment, and IR-780 indocyanine, 
a fluorescent marker for bioimaging analysis. They obtained good 
bioimaging of intracellular localization by Confocal Laser Scanning 
Microscopy (CLSM) and Total Internal Reflection Fluorescence 
Microscopy (TIRFM) in a melanoma MEWO cell line. Later, the 
same group developed new theranostic nanocarriers loaded with both 
colchicine, a cytostatic drug, and coumarin-6, as fluorescent tracer. 
These labeled nanovehicles were efficiently up-taken by several cell 
lines of different origins, including melanoma MEWO cells. The good 
fluorescent signal, as well as the biocompatibility, and the enhanced 
antitumoural activity of colchicines of this nanoformulation suggest 
the potential use as nanotheranostic agents [105].
Vannucci and collaborators [106] developed PEG-based NPs 
functionalized with both the Human protein Ferritin (HFt), and the 
α-Melanocyte-Stimulating Hormone (α-MSH) and also contained 
fluorophore and magnetic resonance imaging tracers to detect 
“in vivo” localization of NP. After the treatment in a spontaneous 
metastatic mouse melanoma model, targeted HFt-MSH-PEG NPs 
accumulated mostly in the primary melanoma lesions, as well as at 
the metastasis level, with high selectivity with respect to other organs.
Interestingly, some metals, such as Au and Gd, can have both 
functions, thus they can have an anti-cancer activity and can be used 
as tracer for imaging. Gd is a paramagnetic metal, normally used in 
contrast agents for MRI. Moreover, it can enhance the efficacy of 
radiation therapy. Thus, the incorporation of Gd into nanoparticle 
allows for the simultaneous use of imaging to guide the radiation 
beams and to locate the tumour, as well as to enhance the toxic 
effect of radiation. Kobt and collaborator [107] have successfully 
treated animals bearing B16-F10 tumours with Gd-based NPs, 
AGuIX®. After radiation therapy, in the AGuIX® treated animals they 
observed an increase of tumour cell death, and improvement of the 
life spans of animals bearing multiple brain melanoma metastases. 
Kang and collaborators [108] have incorporated thermosensitive 
phospholipids, loaded with the drug docetaxel, onto the surface of 
gold NPs (AuNPs) or gold NanoRod (AuNR). Both nanovehicles 
showed enhanced tumour-cell suppression properties towards the 
melanoma B10-F10 cell line. A potential theranostic use is suggested 
by the authors. Indeed, two synergistic anticancer actions can be 
achieved after infrared photo thermal treatment and, thanks to the 
Au particles, they can have bioimaging applications.
An enhanced theranostic activity was achieved by conjugating 
functionalized gold NPs with Single-Wall Carbon NanoTubes 
(SWCNT) [109]. The authors demonstrated a selective imaging and 
efficient photo thermal therapy on UACC903 human melanoma 
cancer cells.
Wang and collaborators [110] have developed very complex 
multifunctional hybrid NPs, composed of gold nanocrystals coated 
on a magnetite-fluorescent porous carbon core-shell. The biomedical 
application of this theranostic nanocarrier includes the possibility of 
bioimaging in multicolor mode, the magnetic/NIR-responsive drug 
release, and the enhanced photo thermal therapy. Mouse melanoma 
B16-F10 cells have been used for this study, thus suggesting their 
potential use in melanoma treatment.
Conclusion
There is no doubt that nanotechnology may offer new therapeutic 
opportunities for the treatment of metastatic melanoma. Given 
the clinical success of immunomodulatory drugs, it is likely we 
will observe more and more pre-clinical studies on strengthening 
their effectiveness, thanks to nanotechnology platforms. Moreover, 
considering the currently on-going clinical trials, the combined 
therapy also seems promising in therapeutic advantages. However, 
it’s difficult to identify the most promising nanomedicine to treat 
melanoma, relying on pre-clinical studies, since these studies 
present several concerns and limitations. The physico-chemical 
properties of delivery systems can modify pharmacokinetics, tumor 
accumulation, and biodistribution. Xenografts represent a useful 
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model to study these parameters for nanoformulations, however, 
tumor characteristics can vary with cell line and size, as well as the 
density and vascularization. Therefore, tumor uptake by the EPR 
effect is expected to be strongly dependent on the cell line used. On 
the other hand, the studies running on the murine melanoma model 
do not completely reflect the complexity of the human melanoma 
cell population. From this point of view, besides the implementation 
of nanotechnological therapies, it could be important to develop 
immunocompetent human models for melanoma research, such 
as three-dimensional human skin reconstruct models containing 
human melanoma cells, with the addition of the immune system cells.
Another concern regards the toxicity studies of NPs with 
clinical potential. Current research lacks a unifying protocol for the 
toxicological profiling of NPs, and studies on the long-term effects on 
human health are also needed [111]. As previously reported, in these 
years the majority of studies on melanoma therapy was regarding new 
platforms for immunotherapy. In melanoma treatments targeting 
the immune response of patients, it is necessary to pay particular 
attention to a possible interaction between nanoparticles and the 
immune system. Although it has been said that nanoparticles are 
unlikely to act as a hapten, inducing a specific IgE production, they 
can induce allergic sensitization (contact dermatitis) and they are 
likely to act as an adjuvant in inducing a specific pattern of cytokines, 
antibodies and cells that favor allergic sensitization to environmental 
allergens [112]. Moreover, the stimulation of inflammatory cytokines 
has been demonstrated to be a key point in nanoparticle-induced 
immunostimulatory reactions [113]. Since an adverse effect of 
immunostimulatory drugs is the risk of developing autoimmune 
disease, these aspects are very important considerations for the choice 
of a drug delivery platform. Therefore, further studies are needed in 
nanotoxicology, to provide safer nanoformulation for the melanoma 
treatment.
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